跳至主要内容
临床试验/NCT05385614
NCT05385614Unknown不适用

Efficacy of Gamified Cognitive Control Training Using de:)Press on Depression Severity add-on to Treatment as Usual

University Hospital Tuebingen2 个研究点 分布在 1 个国家目标入组 112 人开始时间: 2022年5月最近更新:
适应症

试验速览

阶段
不适用
入组人数
112
试验地点
2
主要终点
MADRS

研究概览

简要总结

Depression is one of the most frequent and devastating psychiatric diseases with a substantial bur-den for patients and society. It is specifically associated with dysfunctional activity in brain networks subserving cognitive control of emotional information processing. Normalization of this activity is a hallmark of various treatment approaches. Computerized training of cognitive control has shown antidepressant effects in experimental lab settings and small clinical pilot trials. However, motiva-tion, treatment adherence, and access for patients are major challenges that limit its broader use. To address these challenges, we developed a software application (de:)press®) that integrates gamification elements in a standard cognitive control task to support motivation, usage time, usabil-ity, and therefore symptom reduction. In a previous pilot trial, we were able to document that de:)press® is superior to a non-gamified standard cognitive control training in reducing depression symptomatology. Based on these data, we now designed a full-size confirmatory trial for the pur-pose of testing the hypothesis that de:)press® provides a positive healthcare effect by means of reduction in depression severity compared to treatment as usual (TAU). In this randomized, con-trolled, clinical trial 112 patients will be randomized to the intervention group (IG) with de:)press® additional to TAU, or the control group (CG) receiving only TAU. For a period of 6 weeks, the IG is provided with de:)press®. To prove a stable efficacy of de:)press®, the primary endpoint is the dif-ference in the Montgomery-Åsberg Depression Scale (MADRS) change 4 weeks after the end of training between IG and CG.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male, female, diverse,
  • age >= 18,
  • informed consent,
  • sufficient understanding of German (native speaker or CEFR level B skills or higher),
  • unipolar depression diagnosed according to ICD-10 (F32.0, F32.1, F32.2 or F
  • 0, F32.1, F32.2).
  • consultation with a physician due to depressive symptomatology within the last 6 months

排除标准

  • Inability to give consent,
  • inability to use de:)press® on a tablet or smartphone,
  • acute suicidality,
  • schizophrenia (F20),
  • brief psychotic disorder (F23),
  • schizoaffective disorder (F25),
  • mental disorders due to known physiological conditions (F00 - F09),
  • major depressive disorder, single episode, severe with psychotic features (F32.3),
  • major depressive disorder, recurrent, severe with psychotic features (F33.3),
  • Intellectual disability (F70 - F79).

结局指标

主要结局

MADRS

时间窗: 10 weeks

Difference in symptom severity-reduction (MADRS) between IG and CG at the final examination.

次要结局

  • Response rate(10 weeks)
  • IDS-SR reduction(10 weeks)
  • WHO-5 changes(10 weeks)
  • Remission rate(10 weeks)
  • Self-esteem(10 weeks)
  • WPAI changes(10 weeks)
  • Training sessions(6 weeks)
  • Adverse events(10 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验